Revised physician labelling for neuroleptic drugs: Food and Drug Administration. Notice.
This notice requires that a precaution statement be included in physician labeling of neuroleptic drugs (except rauwolfia alkaloids) stating that these drugs elevate serum prolactin levels and may pose a potential risk to patients.